Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ruxolitinib phosphate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CINC424A2352, CINCB 18424-352, NCT00934544
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 18424-351, NCT00952289
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 14
Sponsor: Other
Protocol IDs: 2010-0450, NCI-2011-02439, NCT01251965
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 18424-255, NCT00639002
INCB018424 in Patients With Advanced Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0925, NCI-2012-01616, NCT00674479
Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Phase: Phase II
Type: Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 18424-260, NCT01340651
Study of Ruxolitinib in Pancreatic Cancer Patients
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 18424-262, NCT01423604
Ruxolitinib in Patients With Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-024, NCT01562873
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HIJAK, NCT01877005
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC1283, NCI-2012-02201, P30CA015083, NCT01732445
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL1011, COG-ADVL1011, NCT01164163
An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INCB 18424-144, NCT01822756
Start Over